Literature DB >> 9394892

Complete deletion of factor IX gene and inhibition of factor IX activity in a labrador retriever with hemophilia B.

M B Brooks1, W Gu, K Ray.   

Abstract

Hemophilia B is a heritable bleeding disorder caused by mutations in the gene coding for coagulation factor IX. The defect has been identified in purebred and mixed-breed dogs. Management of affected dogs requires transfusion of canine blood products supplying active factor IX. Production of inhibitors to factor IX is a complication of transfusion therapy that has been documented as affecting human patients. Risk for producing coagulation inhibitors is greatest for patients having large factor IX gene deletions. To our knowledge, this is the first report of canine factor IX inhibitor production in dogs. The affected dog had clinically severe hemophilia B caused by complete deletion of the factor IX gene and developed resistance to transfusion. Comprehensive evaluation of hemophilic dogs, including assays of specific factor activity, concentration, and factor inhibition, enhances diagnosis and management of this bleeding disorder. Characterization of the molecular defect causing hemophilia is useful for genetic counseling and identifying individuals at highest risk for producing coagulation inhibitors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9394892

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  10 in total

Review 1.  Copy number variation in the domestic dog.

Authors:  Carlos E Alvarez; Joshua M Akey
Journal:  Mamm Genome       Date:  2011-12-04       Impact factor: 2.957

Review 2.  Animal models of hemophilia and related bleeding disorders.

Authors:  Jay N Lozier; Timothy C Nichols
Journal:  Semin Hematol       Date:  2013-04       Impact factor: 3.851

Review 3.  Prevention of spontaneous bleeding in dogs with haemophilia A and haemophilia B.

Authors:  T C Nichols; R A Raymer; H W G Franck; E P Merricks; D A Bellinger; N DeFriess; P Margaritis; V R Arruda; M A Kay; K A High
Journal:  Haemophilia       Date:  2010-05       Impact factor: 4.287

Review 4.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Authors:  Timothy C Nichols; Aaron M Dillow; Helen W G Franck; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Valder R Arruda; Katherine A High
Journal:  ILAR J       Date:  2009

5.  A Line 1 insertion in the Factor IX gene segregates with mild hemophilia B in dogs.

Authors:  Marjory B Brooks; Weikuan Gu; Jennifer L Barnas; Jharna Ray; Kunal Ray
Journal:  Mamm Genome       Date:  2003-11       Impact factor: 2.957

Review 6.  Current animal models of hemophilia: the state of the art.

Authors:  Ching-Tzu Yen; Meng-Ni Fan; Yung-Li Yang; Sheng-Chieh Chou; I-Shing Yu; Shu-Wha Lin
Journal:  Thromb J       Date:  2016-10-04

7.  Christmas disease in a Hovawart family resembling human hemophilia B Leyden is caused by a single nucleotide deletion in a highly conserved transcription factor binding site of the F9 gene promoter.

Authors:  Bertram Brenig; Lilith Steingräber; Shuwen Shan; Fangzheng Xu; Marc Hirschfeld; Reiner Andag; Mirjam Spengeler; Elisabeth Dietschi; Reinhard Mischke; Tosso Leeb
Journal:  Haematologica       Date:  2019-03-07       Impact factor: 9.941

8.  A Single Base Insertion in F9 Causing Hemophilia B in a Family of Newfoundland-Parti Standard Poodle Hybrid Dogs.

Authors:  Henrike Kuder; Liubov Sandzhieva-Vuzzo; Alexandra Kehl; Jonathan M Rappaport; Elisabeth Müller; Urs Giger
Journal:  Genes (Basel)       Date:  2021-09-24       Impact factor: 4.096

Review 9.  Genetics of equine bleeding disorders.

Authors:  Anna R Dahlgren; Fern Tablin; Carrie J Finno
Journal:  Equine Vet J       Date:  2020-06-23       Impact factor: 2.888

Review 10.  Understanding hereditary diseases using the dog and human as companion model systems.

Authors:  Kate L Tsai; Leigh Anne Clark; Keith E Murphy
Journal:  Mamm Genome       Date:  2007-07-26       Impact factor: 2.957

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.